Samsara BioCapital LLC Reduces Position in Janux Therapeutics, Inc. (NASDAQ:JANX)

Samsara BioCapital LLC lessened its stake in shares of Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) by 50.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 11,263 shares of the company's stock after selling 11,263 shares during the quarter. Samsara BioCapital LLC's holdings in Janux Therapeutics were worth $603,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. FMR LLC increased its position in shares of Janux Therapeutics by 10.8% in the fourth quarter. FMR LLC now owns 8,669,941 shares of the company's stock valued at $464,189,000 after acquiring an additional 845,266 shares during the period. Adage Capital Partners GP L.L.C. raised its position in Janux Therapeutics by 47.6% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 3,061,750 shares of the company's stock valued at $163,926,000 after purchasing an additional 986,750 shares during the last quarter. Vanguard Group Inc. lifted its holdings in Janux Therapeutics by 15.6% in the 4th quarter. Vanguard Group Inc. now owns 2,136,332 shares of the company's stock worth $114,379,000 after buying an additional 288,402 shares during the period. Lord Abbett & CO. LLC grew its position in shares of Janux Therapeutics by 80.2% in the 4th quarter. Lord Abbett & CO. LLC now owns 1,267,803 shares of the company's stock worth $67,878,000 after buying an additional 564,322 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD lifted its stake in Janux Therapeutics by 596.3% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,109,978 shares of the company's stock worth $59,429,000 after acquiring an additional 950,557 shares during the period. 75.39% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Janux Therapeutics

In related news, Director Ra Capital Management, L.P. purchased 110,206 shares of Janux Therapeutics stock in a transaction dated Friday, March 7th. The stock was purchased at an average cost of $31.02 per share, with a total value of $3,418,590.12. Following the transaction, the director now owns 10,141,287 shares in the company, valued at approximately $314,582,722.74. The trade was a 1.10 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Andrew Hollman Meyer sold 3,334 shares of the firm's stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $32.15, for a total value of $107,188.10. Following the sale, the insider now directly owns 82,139 shares in the company, valued at approximately $2,640,768.85. The trade was a 3.90 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 10,001 shares of company stock valued at $313,964 in the last ninety days. Corporate insiders own 29.40% of the company's stock.

Wall Street Analysts Forecast Growth

JANX has been the subject of several research reports. William Blair restated an "outperform" rating on shares of Janux Therapeutics in a report on Friday, January 10th. Wedbush reiterated an "outperform" rating and set a $76.00 target price (up previously from $75.00) on shares of Janux Therapeutics in a report on Friday, February 28th. HC Wainwright restated a "buy" rating and issued a $70.00 target price on shares of Janux Therapeutics in a research note on Monday, March 3rd. Finally, Scotiabank reduced their price target on Janux Therapeutics from $62.00 to $41.00 and set a "sector perform" rating on the stock in a research note on Friday, February 28th. One equities research analyst has rated the stock with a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Buy" and a consensus target price of $95.25.

Janux Therapeutics Stock Performance

Janux Therapeutics stock traded down $1.92 during mid-day trading on Monday, hitting $30.97. The company's stock had a trading volume of 842,804 shares, compared to its average volume of 957,126. The company has a 50 day moving average of $29.80 and a 200-day moving average of $42.47. Janux Therapeutics, Inc. has a one year low of $22.52 and a one year high of $71.71. The stock has a market cap of $1.83 billion, a PE ratio of -26.47 and a beta of 3.27.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last issued its earnings results on Thursday, February 27th. The company reported ($0.36) EPS for the quarter, topping analysts' consensus estimates of ($0.49) by $0.13. Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%. On average, equities research analysts forecast that Janux Therapeutics, Inc. will post -1.38 EPS for the current fiscal year.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.